版本:
中国

Biogen Inc (BIIB.O)

BIIB.O ( 纳斯达克 )

231.27USD
19 Jul 2019
涨跌 (%)

$-0.96 (-0.41%)
收盘
$232.23
开盘
$232.86
当日最高
$234.13
当日最低
$231.09
成交量
1,315,791
平均成交量
2,283,856
52 周最高
$388.67
52 周最低
$216.12

概况

Biogen Inc.(原名:Biogen Idec Inc.)是一家生物医药公司。该公司探索、开发及制造用于治疗神经变性疾病、血液病及自身免疫疾病的治疗用药并向患者供应。该公司销售的产品包括:用于多发性硬化症的“TECFIDERA”、“AVONEX”、“PLEGRIDY”、“TYSABRI”及“FAMPYRA”,用于... (更多)

概况

Beta: 0.99
市值(百万): $44,841.73
已发行股本(百万): 193.89
股息: --
股息收益率 (%): --

财务指标

  BIIB.O Industry Sector
P/E (TTM): 9.91 30.63 34.52
EPS (TTM): 23.33 -- --
ROI: 20.60 13.02 12.69
ROE: 33.64 14.18 17.17

UPDATE 2-BioMarin's hemophilia gene therapy data shows promise

May 28 BioMarin Pharmaceutical Inc said on Tuesday data from an early study of its gene therapy for hemophilia A appeared to show blood clotting protein levels were stable, three years after patients were given a one-time infusion of the drug. 全文
05/28 22:21

UPDATE 5-Novartis $2 mln gene therapy for rare disorder is world's most expensive drug

ZURICH/NEW YORK, May 24, Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million. 全文
05/25 06:48

For Anderson family, an early bet on SMA gene therapy

NEW YORK, May 24 When Malachi Anderson was diagnosed with a rare and often deadly disease called spinal muscular atrophy (SMA) as an infant nearly four years ago, his parents Tina and Torence had a decision to make. 全文
05/25 05:26

Novartis CEO plans gene therapy price 'far lower' than $4 mln to $5 mln range

BOSTON, May 22 Novartis AG's top executive said on Wednesday it expects to price its gene therapy for spinal muscular atrophy “far lower” than the $4 million to $5 million figure the Swiss drugmaker has said it could be worth. 全文
05/23 05:21

Swiss stocks - Factors to watch on May 15

ZURICH/BERLIN, May 15 The Swiss blue-chip SMI was seen opening 0.2% higher at 9,425 points on Wednesday, according to premarket indications by bank Julius Baer. 全文
05/15 14:03

UPDATE 1-NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK, May 14 England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza. 全文
05/15 08:02

NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK, May 14 England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza. 全文
05/15 07:01

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

April 25 AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira. 全文
04/25 22:01

UPDATE 1-Biogen first-quarter profit rises 20 pct on Spinraza strength

April 24 Drugmaker Biogen Inc reported a 20 percent rise in first-quarter profit on Wednesday, driven by higher sales of its muscle disease treatment Spinraza. 全文
04/24 18:50

Biogen first-quarter profit rises 20 percent

April 24 Drugmaker Biogen Inc reported a 20 percent rise in first-quarter profit on Wednesday on higher sales of its muscle disease treatment Spinraza. 全文
04/24 18:36

竞争者

  现值 涨跌额
Novartis AG (NOVN.S) CHF92.70 +0.24
Bayer AG (BAYGn.DE) €59.55 +0.79
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €74.57 --
Teva Pharmaceutical Industries Limited (TEVA.TA) 2,750.00 -50.00

收益 vs. 预测